Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results

Perspective Therapeutics Inc (NYSE:CATX) on Monday posted a narrower loss for the third quarter.

The company posted quarterly loss of 27 cents per share, versus a year-ago loss of 35 cents per share. The company’s sales fell to $20.000K from $209.000K in the year-ago period.

“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform,” said Thijs Spoor, Perspective’s Chief Executive Officer. “With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”

Perspective Therapeutics shares fell 2.4% to trade at $0.84 on Tuesday.

These analysts made changes to their price targets on Perspective Therapeutics following earnings announcement.

• Piper Sandler analyst Biren Amin maintained the stock with an Overweight rating and lowered the price target from $14 to $8.
• Wedbush analyst David Nierengarten maintained the stock with an Outperform rating and lowered the price target from $9 to $7.

Considering buying CATX stock? Here’s what analysts think:

Photo via Shutterstock